Wells Fargo & Company MN Boosts Position in Loxo Oncology, Inc. (NASDAQ:LOXO)
Wells Fargo & Company MN increased its stake in Loxo Oncology, Inc. (NASDAQ:LOXO) by 33.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,503 shares of the biopharmaceutical company’s stock after buying an additional 3,875 shares during the period. Wells Fargo & Company MN owned 0.06% of Loxo Oncology worth $653,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. GSA Capital Partners LLP boosted its stake in shares of Loxo Oncology by 14.5% in the fourth quarter. GSA Capital Partners LLP now owns 13,900 shares of the biopharmaceutical company’s stock worth $446,000 after buying an additional 1,760 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares in the last quarter. Nationwide Fund Advisors raised its position in Loxo Oncology by 31.9% in the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 6,632 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Loxo Oncology during the fourth quarter worth $1,812,000. Finally, Candriam Luxembourg S.C.A. raised its position in Loxo Oncology by 28.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 103,000 shares of the biopharmaceutical company’s stock worth $4,334,000 after buying an additional 23,000 shares during the last quarter.
Loxo Oncology, Inc. (NASDAQ LOXO) traded up 2.95% during midday trading on Friday, hitting $72.92. The stock had a trading volume of 163,726 shares. The stock’s market cap is $1.91 billion. The company’s 50 day moving average price is $75.53 and its 200-day moving average price is $53.18. Loxo Oncology, Inc. has a 52-week low of $17.14 and a 52-week high of $83.12.
Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.20. Analysts forecast that Loxo Oncology, Inc. will post ($4.22) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/04/wells-fargo-company-mn-acquires-3875-shares-of-loxo-oncology-inc-nasdaqloxo-updated-updated-updated.html.
A number of research analysts have weighed in on LOXO shares. BTIG Research reaffirmed a “buy” rating and set a $75.00 target price on shares of Loxo Oncology in a report on Tuesday, June 6th. Stifel Nicolaus restated a “buy” rating and issued a $71.00 target price on shares of Loxo Oncology in a research report on Thursday. Zacks Investment Research upgraded Loxo Oncology from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research report on Wednesday, May 3rd. Citigroup Inc. upgraded Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 price objective for the company in a research report on Monday, June 5th. Finally, BidaskClub downgraded Loxo Oncology from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Loxo Oncology presently has a consensus rating of “Buy” and an average target price of $70.83.
In other Loxo Oncology news, Director Keith T. Flaherty sold 7,250 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $45.09, for a total transaction of $326,902.50. Following the transaction, the director now owns 27,141 shares of the company’s stock, valued at $1,223,787.69. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 44.40% of the stock is owned by company insiders.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.